Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation

Tönshoff, Burkhard; David‐Neto, Elias; Ettenger, Robert B.; Filler, Guido; Gelder, Teun van; Goebel, Jens; Kuypers, Dirk; Tsai, Ethan; Vinks, Alexander A.; Weber, Lutz T.; Zimmerhackl, Lothar Bernd

doi:10.1016/j.trre.2011.01.001

Cited by 67 publications

(79 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This observation is also consistent with data from clinical studies, which demonstrated comparable efficacy of MMF regarding the prevention of acute rejection episodes in paediatric renal transplant recipients [2,4]. Data from this and previous studies in paediatric [11] and adult renal transplant recipients [13] also show that IMPDH activity returns to baseline within 4-8 h of administration of MMF.…”

Section: Mpa Concentration (Mg/l) Impdh Inhibition (%)supporting

confidence: 89%

“…Previous clinical studies on the efficacy and safety of MMF in paediatric renal transplant recipients have documented that the incidence of acute rejection is markedly lower in those patients who received an MPA compound compared with those who have received either azathioprine or no antimetabolite [2]. The overall efficacy and safety of MMF appear to be similar in paediatric and adult renal transplant recipients [3,4].…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

Rother

Glander

Vitt

et al. 2012

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Mpa Concentration (Mg/l) Impdh Inhibition (%)supporting

confidence: 89%

Section: Introductionmentioning

confidence: 97%

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

Rother

Glander

Vitt

et al. 2012

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Pre-emptively performed transplantations therefore lead to improved graft survival [8]. Approximately 20% of transplantations in children are performed pre-emptively [8]. …”

Section: Introductionmentioning

confidence: 99%

Long-Term Follow-Up after Paediatric Kidney Transplantation and Influence Factors on Graft Survival: A Single-Centre Experience of 16 years

et al. 2018

View full text Add to dashboard Cite

Introduction: To evaluate graft- and patient survival after paediatric kidney transplantation and detecting influence factors, which affect the post-transplant time. Materials and Methods: We analysed long-term survival rates and complications after paediatric kidney transplantation and searched for predictive parameters for graft function. Results: In 132 patients, 143 kidney transplantations were performed. Graft failure occurred in 25%. Chronic rejections were the leading cause of graft loss (42.9%). Graft survival rates were 92.2% after 1 year, 85.5% after 5 years, 71.1% after 10 years and 62.1% after 15 years. The following parameters strongly influenced graft survival: number of transplants (p = 0.014), year of transplant (p < 0.0001 for 1997–2005), Epo-therapy post-transplant (p = 0.001), hypotension donor (p = 0.027), cold ischemia time (p = 0.023), anastomosis time >50 min (p = 0.008), delayed graft function (p = 0.003) and deceased donation (p = 0.039). The percentage of patients who died was 5.6%. Overall patient survival rates were 99.3% after 1 year, 95.2% after 5 years, 94.2% after 10 years and 90.7% after 15 years. Various types of infections (42.9%) were the main causes of death. Conclusions: The main causes of death after kidney transplantations in paediatric recipients are malignancy and infections. To avoid vascular complications especially in young recipients (<9 years), the cold ischemia time should be as short as possible.

show abstract

“…JCS Guidelines for Drug Therapy in Pediatric Patients With CVD XII. Immunosuppressive for Organ Transplantation (Table 39) [56][57][58][59][60] Cyclosporine (Sandimmune, Neoral) and tacrolimus are approved for use in the transplantation of kidney, liver, heart, lung, pancreas, small intestine, and bone marrow (small intestine is not referred to for Sandimmun Capsule). The safety of these drugs has been established in low-birth-weight newborns, neonates, and infants.…”

Section: Jcs Joint Working Groupmentioning

confidence: 99%

Guidelines for Drug Therapy in Pediatric Patients With Cardiovascular Diseases (JCS 2012)

Group¹

2014

Circ J

View full text Add to dashboard Cite

Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation

Cited by 67 publications

References 48 publications

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid

Long-Term Follow-Up after Paediatric Kidney Transplantation and Influence Factors on Graft Survival: A Single-Centre Experience of 16 years

Guidelines for Drug Therapy in Pediatric Patients With Cardiovascular Diseases (JCS 2012)

Contact Info

Product

Resources

About